L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) - A randomized multicentre trial

Citations of this article
Mendeley users who have this article in their library.

This article is free to access.


Background: Cachexia, a >10% loss of body-weight, is one factor determining the poor prognosis of pancreatic cancer. Deficiency of L-Carnitine has been proposed to cause cancer cachexia. Findings: We screened 152 and enrolled 72 patients suffering from advanced pancreatic cancer in a prospective, multi-centre, placebo-controlled, randomized and double-blinded trial to receive oral L-Carnitine (4 g) or placebo for 12 weeks. At entry patients reported a mean weight loss of 12 ± 2,5 (SEM) kg. During treatment body-massindex increased by 3,4 ± 1,4% under L-Carnitine and decreased (?1,5 ± 1,4%) in controls (p<0,05). Moreover, nutritional status (body cell mass, body fat) and quality-of-life parameters improved under L-Carnitine. There was a trend towards an increased overall survival in the L-Carnitine group (median 519 ± 50 d versus 399 ± 43 d, not significant) and towards a reduced hospital-stay (36 ± 4d versus 41 ± 9d,n.s.). Conclusion: While these data are preliminary and need confirmation they indicate that patients with pancreatic cancer may have a clinically relevant benefit from the inexpensive and well tolerated oral supplementation of L-Carnitine. © 2012 Kraft et al.




Kraft, M., Kraft, K., Gärtner, S., Mayerle, J., Simon, P., Weber, E., … Lerch, M. M. (2012). L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) - A randomized multicentre trial. Nutrition Journal, 11(1). https://doi.org/10.1186/1475-2891-11-52

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free